Immunogenic compositions comprising hmgb1 polypeptides
AssigneesMedImmune, LLC, The Feinstein Institute for Medical Research
InventorsDavorka Messmer, Kevin Tracey, Peter Kiener, Scott Alban
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specifically, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specifically, this invention provides novel fusion proteins comprising an isolated HMGB1 polypeptide and an antigen such that administration of these fusion proteins provides the two signals required for native T-cell activation.
Claims12
An immunogenic composition comprising a fusion polypeptide, wherein said fusion polypeptide comprises an HMGB1 polypeptide or a functional variant thereof fused to a heterologous antigen.
An immunogenic composition comprising an HMGB1 polypeptide or a functional variant thereof and a heterologous antigen.
Dependencies are inferred from the claim text.